Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000522723 | SCV000620483 | uncertain significance | not provided | 2024-10-21 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function |
Labcorp Genetics |
RCV000634755 | SCV000756098 | uncertain significance | Ehlers-Danlos syndrome, kyphoscoliotic type 1 | 2022-08-16 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 556 of the PLOD1 protein (p.Tyr556Cys). This variant is present in population databases (rs146360295, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with PLOD1-related conditions. ClinVar contains an entry for this variant (Variation ID: 451743). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ce |
RCV000522723 | SCV001247281 | uncertain significance | not provided | 2019-08-01 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000522723 | SCV001712971 | uncertain significance | not provided | 2019-11-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002404348 | SCV002708423 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2023-12-12 | criteria provided, single submitter | clinical testing | The c.1667A>G (p.Y556C) alteration is located in exon 16 (coding exon 16) of the PLOD1 gene. This alteration results from a A to G substitution at nucleotide position 1667, causing the tyrosine (Y) at amino acid position 556 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV000634755 | SCV002791631 | uncertain significance | Ehlers-Danlos syndrome, kyphoscoliotic type 1 | 2022-04-05 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004525959 | SCV005040571 | uncertain significance | not specified | 2024-03-31 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV000522723 | SCV005186464 | uncertain significance | not provided | criteria provided, single submitter | not provided |